---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Dosage forms and strengths"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Dosage forms and strengths. Topics: Strengths filed in the NDA: aroxybutynin and atomoxetine base with hydrochloride equivalents, Dosage form: fixed-dose oral tablet taken once nightly, Strength notation in publications: aroxybutynin 2.5 mg/atomoxetine 75 mg, and Phase 3 investigational product supply: run-in blister pack and target-dose bottle. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Strengths filed in the NDA: aroxybutynin and atomoxetine base with hydrochloride equivalents

> “In July 2026, the FDA accepted for review the NDA filing of Oxnimbi 2.3mg of aroxybutynin and 37.5mg atomoxetine (equivalent to 2.5mg of aroxybutynin hydrochloride and 42.85mg of atomoxetine hydrochloride) or 2.3mg aroxybutynin and 75mg atomoxetine (equivalent to 2.5mg of aroxybutynin hydrochloride and 85.7mg of atomoxetine hydrochloride) for the treatment of adults with OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.2-2"></a>

### Dosage form: fixed-dose oral tablet taken once nightly

> “It is a fixed-dose  oral tablet anti-apneic neuromuscular modulator co-formulated with our novel anti-muscarinic aroxybutynin (2.3mg) combined with the NRI atomoxetine (75mg) equivalent to 2.5mg of aroxybutynin hydrochloride and 85.7mg of atomoxetine hydrochloride.”
> “Oxnimbi is formulated into a small tablet that is taken once nightly, just prior to bedtime.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.2-3"></a>

### Strength notation in publications: aroxybutynin 2.5 mg/atomoxetine 75 mg

> “AD109 (investigational fixed-dose oral combination of aroxybutynin 2.5 mg/atomoxetine 75 mg) is designed to target neuromuscular dysfunction in OSA.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.2-4"></a>

### Phase 3 investigational product supply: run-in blister pack and target-dose bottle

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
